ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SYNC Syncona Limited

124.60
1.00 (0.81%)
27 Feb 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.00 0.81% 124.60 124.00 124.20 125.40 123.60 124.00 433,107 16:35:20
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Trust,ex Ed,religious,charty -39.79M -56.02M -0.0840 -14.76 826.75M
Syncona Limited is listed in the Trust,ex Ed,religious,charty sector of the London Stock Exchange with ticker SYNC. The last closing price for Syncona was 123.60p. Over the last year, Syncona shares have traded in a share price range of 105.00p to 172.40p.

Syncona currently has 666,733,588 shares in issue. The market capitalisation of Syncona is £826.75 million. Syncona has a price to earnings ratio (PE ratio) of -14.76.

Syncona Share Discussion Threads

Showing 18901 to 18925 of 18925 messages
Chat Pages: 757  756  755  754  753  752  751  750  749  748  747  746  Older
DateSubjectAuthorDiscuss
27/2/2024
11:25
Looking better here.........
chrisdgb
02/11/2023
11:52
Autolus looking promising.
the shuffle man
29/9/2023
14:36
Desperate stuff.
shep22
29/9/2023
09:10
Share buy back seems to have stopped the drop for now.
the shuffle man
27/9/2023
21:49
Syncona is in serious decline because of bad management, the issue must be addressed and quickly.
shep22
22/9/2023
17:56
Another round of selling coming, management charges urgently required.
shep22
21/9/2023
11:09
I made a small amount of money out of Sync several years ago.
Just having another look again given the bombed out share price
All of these sort of businesses have been hard hit by the rise in interest rates producing a double whammy of increased funding costs for portfolio companies and less opportunity to get an ipo away.
Having said that a point is reached when sentiment is too negative and I think we are nearing that point, having said that, as previous posters have said, the business in now under serious pressure to produce some positive news flow which goes beyond just "we have made good progress with clinical trials"

salpara111
19/9/2023
18:05
I've learned never to average down on your losers, but average up on your winners. If institutions are dumping this, the only way is down.
chc15
18/9/2023
11:06
They need some good news on some of their more mature portfolio companies to try and change this poor sentiment. Hopefully we will hear more news on Autolus soon. Trading at a big discount to NAV and holding a lot of cash. I have done the dreaded thing and averaged down.
the shuffle man
18/9/2023
09:31
Yeh gotta be institutions dumping now, wonder if Blackrock have had enough.
chc15
18/9/2023
08:53
EPIC currently describes the share price :(
spectoacc
12/9/2023
13:02
Can somebody please tell me how Marin Murphy is still in a job, he has destroyed shareholder value.
shep22
11/9/2023
14:07
Yes, very disappointing. At least they got £326m upfront, so the original decision to sell was a good call. The £54.5m write-off of deferred consideration is equivalent to 8.1p per share, so net asset value is now 176.5p based on the latest quarterly update, of which over 51% is in cash. Discount to asset value is now 32%, so still looking very cheap but this is poor for sentiment and to be honest they need some good news to emerge from their drug portfolio to change that.
tiger blue
11/9/2023
10:46
Oh dear, not good news, I'll hold off buying here. Blackrock must be losing tons on this.
chc15
06/9/2023
12:52
Ok thx, yeh i think they will recover, checking on shareholders, Blackrock bought a huge stake in these, so we'll see.
chc15
06/9/2023
12:23
Hugely out of favour and ignored, as you will know by being the first post since your exit one in March! While I made a lot of money from this by virtue of having them from BACIT at 100p launch and exiting average 248, and by having far more of them than was sensible, I did buy 10% of the original holding back in the mid 160's, so long and wrong on those. They are far below nav and unloved but I think there will be better days ahead when the sector turns, which might be helped once we get a turn in the interest rate cycle, as higher rates have been a big headwind for the sector.
tiger blue
06/9/2023
11:45
Checking back on this dog, might be tempted to nibble back in here, seems bio still out of favour.
chc15
09/3/2023
13:40
I got out of this last week, going nowere.
chc15
08/3/2023
17:05
Lets hope not. Just bought some. trading at a decent discount with lots of cash. They have a decent track record. Just need sentiment to change towards Biotechs. There must be a persistent seller around at the moment. Lets hope they are done soon.
the shuffle man
08/3/2023
14:12
Not more than..........
spectoacc
08/3/2023
13:05
3 yr lows, can this drop much further?
chc15
08/2/2023
12:00
Not a great q3, shares taking a dive again , 6% drop, may top up a bit..
chc15
26/1/2023
09:56
Having a small nibble here, the share price is dire..
chc15
20/11/2022
21:43
I agree that it was an ambitious statement, but not one they had to make and at this stage unlikely to move the dial much on the share price. They are however serious people who know their sector well, with excellent contacts to enable early access to good science, and it was intriguing that they made it at all. I think they have learned a lot since launch, but still delivered a portfolio IRR of 26% to date, and stepping up the number of company launches with additional recruitment should give a boost. Despite some excellent exits NASDAQ has not been a happy place for their quoted companies, hence what reads as a shift to holding privately to exit with 'like minded' investors. That's not necessarily a bad thing, as Gyroscope had the float badly handled and pulled, but despite that soon after got a nice bid from Novartis. That was their second retinal area sale and they are back in with another new retinal venture. At the end of the day I am there on the basis that anywhere below nav they look on the cheap side, and if they get somewhere close to their target I will be well rewarded. Incidentally, if my use of the compound calculator is correct, it would take a 15% compound return to get to £5 billion over the 10 years. Yes, they have the drag of the capital pool to contend with, but given the portfolio IRR they have achieved to date it's not out of the question.
tiger blue
20/11/2022
20:59
So was I, so I watched the webcast and have to say that no real guidance was given beyond that the sector itself has tremendous opportunities, and that SYNC is upping its game a tad by taking on more staff. I was hoping that in Q&A at the end one of the analysts would ask the (obvious) question, but none did. They are not upping the amount they invest pa, at least for the time being, and they are intent on keeping a big cash balance - which is sensible but a big drag on returns. Of course, it could be that they are supremely confident one of their current port cos is going to go to the moon, and the beauty of bio investing is that success can bring huge value add. Hmmm...
rambutan2
Chat Pages: 757  756  755  754  753  752  751  750  749  748  747  746  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com